drugset / Trial / NCT05677763

OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness

NCT05677763

Phase 4 Active not recruiting 525 enrolled OM Pharma SA
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will assess the efficacy and safety of OM-85 compared to placebo in reducing the number of respiratory tract infections (RTIs) in children aged between 6 months and 5 years.

Timeline

Start
2022-12-12
Primary completion
2026-03-10
Completion
2026-09-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Broncho-Vaxom Other / unclassified 3.5 mg Oral